Home > Research > Publications & Outputs > An empirical survey on biobanking of human gene...
View graph of relations

An empirical survey on biobanking of human genetic material and data in six EU countries.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

  • Isabelle Hirtzlin
  • Christine Dubreuil
  • Nathalie Préaubert
  • Jenny Duchier
  • Brigitte Jansen
  • Jürgen Simon
  • Paula Lobatao De Faria
  • Anna Perez-Lezaun
  • Bert Visser
  • Garrath D. Williams
  • Anne Cambon-Thomsen
  • The EUROGENBANK consortium
<mark>Journal publication date</mark>06/2003
<mark>Journal</mark>European Journal of Human Genetics
Issue number6
Number of pages14
Pages (from-to)475-488
Publication StatusPublished
<mark>Original language</mark>English


Biobanks correspond to different situations: research and technological development, medical diagnosis or therapeutic activities. Their status is not clearly defined. We aimed to investigate human biobanking in Europe, particularly in relation to organisational, economic and ethical issues in various national contexts. Data from a survey in six EU countries (France, Germany, the Netherlands, Portugal, Spain and the UK) were collected as part of a European Research Project examining human and non-human biobanking (EUROGENBANK, coordinated by Professor JC Galloux). A total of 147 institutions concerned with biobanking of human samples and data were investigated by questionnaires and interviews. Most institutions surveyed belong to the public or private non-profit-making sectors, which have a key role in biobanking. This activity is increasing in all countries because few samples are discarded and genetic research is proliferating. Collections vary in size, many being small and only a few very large. Their purpose is often research, or research and healthcare, mostly in the context of disease studies. A specific budget is very rarely allocated to biobanking and costs are not often evaluated. Samples are usually provided free of charge and gifts and exchanges are the common rule. Good practice guidelines are generally followed and quality controls are performed but quality procedures are not always clearly explained. Associated data are usually computerised (identified or identifiable samples). Biobankers generally favour centralisation of data rather than of samples. Legal and ethical harmonisation within Europe is considered likely to facilitate international collaboration. We propose a series of recommendations and suggestions arising from the EUROGENBANK project.